114 related articles for article (PubMed ID: 28761744)
1. Discussing and prescribing expensive unfunded anticancer drugs in Australia.
Karikios DJ; Mileshkin L; Martin A; Ferraro D; Stockler MR
ESMO Open; 2017; 2(2):e000170. PubMed ID: 28761744
[TBL] [Abstract][Full Text] [Related]
2. Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.
Wong SK; Gondara L; Gill S
Curr Oncol; 2021 Nov; 28(6):4748-4755. PubMed ID: 34898584
[TBL] [Abstract][Full Text] [Related]
3. Recommending Unfunded Innovative Cancer Therapies: Ethical vs. Clinical Perspectives among Oncologists on a Public Healthcare System-A Mixed-Methods Study.
Bashkin O; Dopelt K; Asna N; Davidovitch N
Curr Oncol; 2021 Aug; 28(4):2902-2913. PubMed ID: 34436020
[TBL] [Abstract][Full Text] [Related]
4. Variation and consternation: access to unfunded cancer drugs in Canada.
Berry SR; Evans WK; Strevel EL; Bell CM
J Oncol Pract; 2012 Jan; 8(1):35-9. PubMed ID: 22548009
[TBL] [Abstract][Full Text] [Related]
5. Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia.
Agarwal A; Karikios DJ; Stockler MR; Morton RL
PLoS One; 2022; 17(10):e0273620. PubMed ID: 36269711
[TBL] [Abstract][Full Text] [Related]
6. Do oncologists discuss expensive anti-cancer drugs with their patients?
Thomson J; Schofield P; Mileshkin L; Agalianos E; Savulescu J; Zalcberg J; Jefford M
Ann Oncol; 2006 Apr; 17(4):702-8. PubMed ID: 16418309
[TBL] [Abstract][Full Text] [Related]
7. Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data.
Goldacre B; Reynolds C; Powell-Smith A; Walker AJ; Yates TA; Croker R; Smeeth L
BMJ Open; 2019 Feb; 9(2):e026886. PubMed ID: 30813120
[TBL] [Abstract][Full Text] [Related]
8. The utility of cost discussions between patients with cancer and oncologists.
Zafar SY; Chino F; Ubel PA; Rushing C; Samsa G; Altomare I; Nicolla J; Schrag D; Tulsky JA; Abernethy AP; Peppercorn JM
Am J Manag Care; 2015 Sep; 21(9):607-15. PubMed ID: 26618364
[TBL] [Abstract][Full Text] [Related]
9. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
[TBL] [Abstract][Full Text] [Related]
10. Paternalism in practice: informing patients about expensive unsubsidised drugs.
Dare T; Findlay M; Browett P; Amies K; Anderson S
J Med Ethics; 2010 May; 36(5):260-4. PubMed ID: 20439327
[TBL] [Abstract][Full Text] [Related]
11. Rising cost of anticancer drugs in Australia.
Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
[TBL] [Abstract][Full Text] [Related]
12. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
13. Less than ideal: how oncologists practice with limited drug access.
Chan KK; Wong B; Siu LL; Straus SE; Chang J; Berry SR
J Oncol Pract; 2012 May; 8(3):190-5. PubMed ID: 22942815
[TBL] [Abstract][Full Text] [Related]
14. Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?
Shrank WH; Joseph GJ; Choudhry NK; Young HN; Ettner SL; Glassman P; Asch SM; Kravitz RL
Am J Manag Care; 2006 Sep; 12(9):545-51. PubMed ID: 16961443
[TBL] [Abstract][Full Text] [Related]
15. General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study.
Tudball J; Reddel HK; Laba TL; Jan S; Flynn A; Goldman M; Lembke K; Roughead E; Marks GB; Zwar N
Aust Health Rev; 2019 Jul; 43(3):246-253. PubMed ID: 29754592
[TBL] [Abstract][Full Text] [Related]
16. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
Schrag D; Hanger M
J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
[TBL] [Abstract][Full Text] [Related]
17. To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option.
Mileshkin L; Schofield PE; Jefford M; Agalianos E; Levine M; Herschtal A; Savulescu J; Thomson JA; Zalcberg JR
J Clin Oncol; 2009 Dec; 27(34):5830-7. PubMed ID: 19786663
[TBL] [Abstract][Full Text] [Related]
18. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
19. Approved but non-funded vaccines: accessing individual protection.
Scheifele DW; Ward BJ; Halperin SA; McNeil SA; Crowcroft NS; Bjornson G
Vaccine; 2014 Feb; 32(7):766-70. PubMed ID: 24374500
[TBL] [Abstract][Full Text] [Related]
20. What determines the timing of discussions on forgoing anticancer treatment? A national survey of medical oncologists.
Mori M; Shimizu C; Ogawa A; Okusaka T; Yoshida S; Morita T
Support Care Cancer; 2019 Apr; 27(4):1375-1382. PubMed ID: 30145739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
